Tractinostat/Valganciclovir

N/A

Report date: 2023/12/14 15:53:31

Base Information

Drug NameTractinostat/Valganciclovir
Drug Alias NameNanatinostat+ValganciclovirNanatinostat/ValganciclovirNana-val
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHistone deacetylase inhibitorsDNA-directed DNA polymerase inhibitors
TargetsHistone deacetylaseDNA-directed DNA polymerase
Therapy Area/IndicationsLymphoproliferative DisordersNasopharyngeal CarcinomaLymphoma, Large B-Cell, Diffuse +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[15] 
CombinationsYes Valganciclovir HydrochlorideTractinostat
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesViracta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesViracta Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoproliferative Disorders
Inactive IndicationsNasopharyngeal CarcinomaLymphoma, Large B-Cell, DiffuseHodgkin Disease +[5] 

Other Information

ATC CodeN/A
Related LinksN/A